Bejarano-Lara J, Llamas-Macías FJ, Nuño-Escobar C, Calderón-Llamas MA

Language: Spanish
References: 13
Page: 54-60
PDF size: 132.27 Kb.

ABSTRACT

Objective. To determine the concentration of inflammatory biomarkers interleukin-6 (IL-6), soluble vascular cytoadhesion molecule 1 (sSVCAM-1), tissue inhibitor of metalloproteinase 1 (TIMP-1) and Creactive protein (CRP) in patients with disease peripheral arterial (PAD) before and after endovascular revascularization surgery.
Material and methods. An analytical cross-sectional study was carried out with a sample of 20 patients. The concentrations of IL-6, sSVCAM-1, TIMP-1 and CRP were determined by ELISA in patients with lower limb EAP, before and after the endovascular revascularization surgery in the Service of Angiology at the Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, from February 01, 2017 to July 31, 2017. Inferential analysis: Wilcoxon test. It is calculated in 95% confidence intervals. Values of p ‹ 0.05 were considered statistically significant.
Results. They are expressed in medians, with superior and inferior interquartile ranges. The median CRP presented a revascularization of 2.645 mg /L (2.375-2.8125 mg/L). Subsequently, an average of 0.765 mg/L (0.675-0.85 mg/L). For sVCAM-1 it covers median of 498.81 ng/dL (489.9775-513.8975 ng/dL). The median after revascularization was 268.55 ng/dL (247.85-304.405 ng/dL). The baseline median of IL-6 was 20,315 pg/mL (18.2475-21.85 pg/mL). Already revascularized, it covers median 5.93 pg/mL, (4.45-7.35 pg/mL). For TIMP-1, they obtained a prior prior to the procedure of 245.4 ng/mL (226.8025-249.575 ng/mL); after it, we observed a decrease, with a median of 89.94 ng/mL (81.3425- 99.81 ng/mL).
Conclusion. Determination of inflammatory biomarkers is useful to help predict the response to surgical treatment of the endovascular type.

REFERENCES

1. Kleinegris MF, Konings J, Daemen JW, Henskens Y, De Laat B, Spronk HMH, et al. Increased Clot Formation in the Absence of Increased Thrombin Generation in Patients with Peripheral Arterial Disease: A Case-Control Study. Front Cardiovasc Med 2017; 4(23).

2. Cronenwett JL, Johnston KW. Arteriogenesis y angiogenesis. Rutherford's Vasular Surgery. Vol. 1. Elsevier; 2014, p. 99.

3. Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. Circ Res 2017; 120(8): 1326-40.

4. Kikuchi R, Nakamura K, MacLauchlan S, Thi-Minh Ngo D, Shimizu I, Fuster JJ, et al. An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat Med 2014; 20(12): 1464-71.

5. Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology and potential biomarkers for peripheral artery disease. Int J Mol Sci 2015; 16(5): 11294-322.

6. Norgren L, Hiatt WR, Dormandy JA, et al. Intersociety consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007; 33 (Suppl. 1): s1-s75.

7. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Vascular Medicine 2004; 110(6): 738-43.

8. Macías C, Villaescusa R, Boffil V, Cordero G. Moléculas de adhesión endoteliales ICAM-1, VCAM-1 y E-selectina en pacientes con síndrome coronario agudo. Rev Esp Cardiol 2003; 56(2): 137-44.

9. Guo XK, Zhao WQ, Kondo C, Shimojo N, Yamashita K, Aoki T, et al. Tissue inhibitors of metalloproteinases-1 (TIMP-1) and -2(TIMP-2) are major serum factors that stimulate the TIMP-1 gene in human gingival fibroblasts. Biochim Biophys Acta - Mol Cell Res 2006; 1763(3): 296-304.

10. Cauley JA, Kassem AM, Lane NE, Thorson S. Prevalent peripheral arterial disease and inflammatory burden. BMC Geriatr 2016; 16(1): 213.

11. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, enal, Mesenteric, and Abdominal Aortic). ACC/AHA Practice Guidelines 2006; 113: e463-e465.

12. Tayebjee MH, Tan KT, MacFadyen RJ, Lip GY. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: Relationship to disease severity. J Intern Med 2005; 257(1): 110-116.

13. Bosevski M, Bosevska G, Stojanovska L. Influence of fibrinogen and C-RP on progression of peripheral arterial disease in type 2 diabetes: a preliminary report. Cardiovascular Diabetology, BioMed Central 2013, 12: 29.